Summary & Overview
HCPCS J0736: Injection, Clindamycin Phosphate 300 mg
HCPCS Level II code J0736 denotes a 300 mg injection of clindamycin phosphate, a parenteral antibiotic used across inpatient and outpatient settings. Nationally, accurate coding of injectable antimicrobials matters for medication administration records, payer adjudication, and monitoring antibiotic utilization trends. This code applies to therapeutic medication administration delivered in ambulatory infusion centers, hospital inpatient and outpatient departments, emergency departments, and physician offices.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, typical sites of service, common modifier considerations (listed separately), and what to expect in payer coverage patterns. The publication outlines benchmarks for utilization and reimbursement structures where available, highlights recent policy updates that affect injectable drug billing, and summarizes operational implications for billing and revenue cycle teams.
Intended audiences include revenue cycle managers, clinical coders, pharmacists, and policy analysts seeking a national-level reference on billing and administrative handling of injectable clindamycin.
Billing Code Overview
HCPCS Level II code J0736 represents an injection of clindamycin phosphate, 300 mg. This code describes a single administration of the antibiotic clindamycin in injectable form.
-
Service type: Therapeutic medication administration
-
Typical site of service: Ambulatory infusion centers, hospital inpatient and outpatient settings, emergency departments, and physician offices where parenteral antibiotics are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old adult presenting to an outpatient infusion center or emergency department with a serious skin and soft tissue infection (for example, cellulitis or an abscess) caused by susceptible anaerobic or gram-positive organisms, or a patient with a documented penicillin allergy requiring alternative therapy. The treating clinician orders a single intramuscular or intravenous dose of J0736 (injection, clindamycin phosphate, 300 mg) to provide rapid bacteriostatic/bactericidal coverage. The clinical workflow includes evaluation by an MD/DO or advanced practice provider, confirmation of indication and allergy history, verification of weight and renal/hepatic status, informed consent for parenteral antibiotic administration, preparation of the J0736 dose by nursing or pharmacy staff, administration via IV push, IV piggyback, or IM injection per facility protocol, observation for adverse reactions (including anaphylaxis or gastrointestinal side effects), and documentation of lot number, dose, route, site, and any applicable modifier reporting. Typical sites of service are outpatient clinic infusion centers, urgent care, emergency departments, or inpatient wards when IV/IM parenteral antibiotic therapy is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |